Sign Out
Leflunomide is indicated for the treatment of adult patients with: active rheumatoid arthritis (to reduce signs and symptoms, to slow radiographic progression of joint destruction and to improve physical function) as a "disease-modifying antirheumatic drug" (DMARD); active psoriatic arthritis.
Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g., methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit/risk aspects.
Moreover, switching from leflunomide to another DMARD without following the washout procedure (see Precautions) may also increase the risk of serious adverse reactions even for a long time after the switching.
